BioIVT Acquires Biological Specialty Corporation

XML Feed

BioIVT Acquires Biological Specialty Corporation

BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it has acquired Biological Specialty Corporation (BSC), a supplier of human blood products and components to the life sciences research community for more than 37 years. BSC is headquartered in Colmar, Pennsylvania, with two additional FDA-registered donor centers in Allentown, Pennsylvania and Reading, Pennsylvania.

“We are delighted that BSC is joining BioIVT,” said BioIVT Chief Executive Officer (CEO) Jeff Gatz. “BSC brings a decades-long reputation for top-notch quality, compliance and customer service. BSC’s capabilities will enable BioIVT to provide same-day fresh material to the biotech industry in the Northeast Corridor. BSC also significantly strengthens BioIVT’s immunology business line, enabling BioIVT to provide a full range of blood-derived cells and cellular products ranging from leukopak-derived peripheral blood mononuclear cells (PBMCs) to CD34 stem cells.”

“In BioIVT, we have found a like-minded partner whose desire to provide the highest quality research samples and top-notch customer service equals our own,” added BSC CEO Jeff Widdoss. “Together, we will be able to help our clients accelerate their drug discovery and immunotherapy research.”

Emphasizing its commitment to providing the highest quality biospecimens, BSC’s donors are all screened according to AABB guidelines, and its research blood products all undergo the complete battery of FDA-required infectious disease state tests.

BioIVT will retain BSC’s three locations and all of its employees. Financial details about this transaction were not disclosed.